Skip to main content

Table 6 Deterministic sensitivity analysis results according to PFS. Amounts are presented in MXN pesos

From: Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations

TKI Mean total cost Incremental Cost Effectiveness Incremental Effectiveness ICER
5% discount (case-base)
 Gefitinib $161,800.00 8.18
 Erlotinib $215,700.00 $53,900.00 6.70 −1.48 Dominated
 Afatinib $348,200.00 $186,400.00 9.46 1.28 $145,625.00
No discount (0%)
 Gefitinib $206,502.36 10.44
 Erlotinib $275,293.93 $68,791.58 8.55 −1.89 Dominated
 Afatinib $444,401.24 $237,898.88 12.07 1.63 $145,625.00
3% discount
 Gefitinib $139,570.10 7.06
 Erlotinib $186,064.71 $46,494.61 5.78 −1.28 Dominated
 Afatinib $300,360.38 $160,790.28 8.16 1.10 $145,625.00
7% discount
 Gefitinib $115,361.16 5.83
 Erlotinib $153,791.12 $38,429.96 4.78 −1.06 Dominated
 Afatinib $248,261.79 $132,900.62 6.74 0.91 $145,625.00